Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

A股创新药概念集体回调，迈威生物跌超10%，百济神州、信立泰双双跌超8%，益方生物、舒泰神、热 景生物、百利天恒、诺诚健华等跌幅靠前。 ...

早盘 创新药概念集体回调， 迈威生物跌超10%， 百济神州、 信立泰双双跌超8%， 益方生物、 舒泰 神、 热景生物、 百利天恒、 诺诚健华等跌幅靠前。 ...

Core Viewpoint - The Sci-Tech Innovation Board (STAR Market) continues to play a crucial role in supporting technological innovation in China amid a complex economic environment in 2024, focusing on high-quality development in key industries such as integrated circuits, artificial intelligence, innovative pharmaceuticals, and advanced manufacturing [1] Group 1: Company Performance - In 2024, STAR Market companies achieved a total operating revenue of 1,422.17 billion yuan, a year-on-year increase of 0.24%, with nearly 70% of companies reporting revenue growth [2] - The net profit for the year reached 47.52 billion yuan, with 50% of companies experiencing profit growth, and 32 companies turning losses into profits [2] - Private enterprises, which account for over 80% of STAR Market companies, showed resilience and vitality, with 154 companies doubling their revenue post-listing and 70 companies achieving doubled or turned profitable net income [2] Group 2: Innovation and R&D - STAR Market companies increased their R&D investment, with total R&D expenditure reaching 168.08 billion yuan in 2024, exceeding net profit by 2.5 times, and a year-on-year growth of 6.4% [7] - The median R&D intensity among STAR Market companies was 12.6%, leading all A-share sectors, with 107 companies maintaining an R&D intensity above 20% for three consecutive years [7] - A total of 20 companies listed under the fifth set of standards have made significant progress, with 18 achieving core product launches and 16 companies reporting revenues exceeding 100 million yuan [3] Group 3: Market Reforms and Financing - Recent capital market reforms, including the "STAR Market Eight Articles" and "Merger and Acquisition Six Articles," have enhanced the adaptability and inclusiveness of the STAR Market, facilitating high-quality industrial integration [4] - The STAR Market has seen 100 new industry mergers and acquisitions since June 2024, with disclosed transaction amounts exceeding 24.7 billion yuan [4] - Eight companies have disclosed refinancing plans under the new "light asset, high R&D investment" criteria, with a total financing scale exceeding 17.5 billion yuan [5] Group 4: International Expansion and Competitiveness - Over 80% of STAR Market companies focus on core products aimed at import substitution and self-control, with over 380 companies achieving international advanced levels in their products or technologies [8] - In 2024, STAR Market companies reported total overseas revenue of 430.36 billion yuan, a year-on-year increase of 6.1%, with 173 companies experiencing over 30% growth in overseas revenue [8] - High-margin products are increasingly penetrating global markets, with the median gross margin for overseas sales reaching 40.8% [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is increasing its R&D investment and has initiated its first overseas registration clinical trial for its core product BL-B01D1 [7] - The company reported a significant decline in revenue and profit for Q1 2025, primarily due to the absence of large intellectual property licensing income that was recognized in the same period last year [7] - BL-B01D1 has over 40 ongoing clinical studies, with several in Phase III trials, indicating strong potential for becoming a standard treatment for various cancers [7] - The company forecasts revenues of 2.018 billion for 2025, with growth expected in subsequent years, reflecting the potential of its innovative products [7] Financial Summary - Total revenue for 2023 is projected at 561.87 million, with a significant increase to 5,822.72 million in 2024, followed by a decrease to 2,018 million in 2025 [1] - The net profit attributable to the parent company is expected to be a loss of 780.50 million in 2023, with a recovery to a profit of 3,707.51 million in 2024, followed by further losses in the subsequent years [1] - The latest diluted EPS is projected to be (1.95) in 2023, improving to 9.25 in 2024, but declining again in the following years [1]

投资要点 事件：公司2025 年一季度营业收入6744.0 万元，同比减少98.77%;归属于母公司所有者的净亏损5.31 亿 元，上年同期净利润50.05 亿元。 核心产品BL-B01D1（EGFR×HER3 双抗ADC）国内进展更新：截至25 年4 月，BL-B01D1 已开展40 余 项临床研究，包括8 个单药后线疗法III 期注册临床，覆盖非小细胞肺癌、小细胞肺癌、乳腺癌、尿路上 皮癌、食管癌、鼻咽癌适应症；以及联合奥希替尼治疗一线EGFR 突变非小细胞肺癌已进入III期临床试 验阶段并完成首例受试者入组；8 个与PD1 联合用于一线治疗的II 期临床等。2025 年ASCO 会议，BL- B01D1 有望进一步读出多项临床数据，包括非小细胞肺癌、小细胞肺癌以及卵巢癌等；后线鼻咽癌和 食管癌25 年有望读出III 期期中分析数据，并于25 年底或26 年递交上市申请；此外，多个III 期临床有 望完成患者入组，并新开多个后线患者的III 期临床以及1L 患者的III 期临床。BL-B01D1 联合疗法有潜 力成为肿瘤一线治疗的标准疗法和下一个超级重磅药物。 BL-B01D1 首个海外注册临床启动：25 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is increasing its R&D investment and has initiated its first overseas registration clinical trial for its core product BL-B01D1 [7] - The company reported a significant decline in Q1 2025 revenue and net profit due to the absence of large intellectual property licensing income, which was present in the same period last year [7] - BL-B01D1 has over 40 ongoing clinical studies, with several in advanced stages, indicating strong potential for future growth and market entry [7] - The company forecasts revenues of 2.018 billion for 2025, with projections of 2.035 billion and 2.541 billion for 2026 and 2027 respectively, reflecting a strong growth trajectory [7] Financial Summary - Total revenue for 2023 is projected at 561.87 million, with a significant increase to 5,822.72 million in 2024, followed by a decrease to 2,018.00 million in 2025 [1] - The net profit attributable to the parent company is expected to be a loss of 780.50 million in 2023, with a recovery to a profit of 3,707.51 million in 2024, followed by further losses in subsequent years [1] - The latest diluted EPS is projected to be (1.95) in 2023, improving to 9.25 in 2024, and then declining to (1.34) in 2025 [1] - The company’s market capitalization is approximately 114.72 billion, with a circulating A-share market value of about 29.44 billion [5]

Core Insights - The Chinese innovative drug industry is experiencing a positive trend, with increasing industry prosperity and significant breakthroughs in product development by various companies [1][2][3] - The AACR annual meeting showcased the strength of Chinese innovative drug research, with 126 companies presenting nearly 300 new drug research results [2] - Several companies reported impressive financial results, indicating a recovery and growth in the sector [4][5][6] Industry Developments - The AACR meeting highlighted the growing influence of Chinese innovative drugs, with over 80 ADC studies and nearly 40 bispecific antibody studies presented [2] - Notable approvals include the new BTK inhibitor from Innovent Biologics and the PD-1/VEGF bispecific antibody from Kangfang Biotech, both receiving regulatory approval for cancer treatment [3] - The industry is seeing a trend of improved financial performance, with companies like Heng Rui Pharma reporting a 22.63% increase in revenue and a 47.28% increase in net profit [4] Financial Performance - Heng Rui Pharma achieved a revenue of 27.985 billion yuan, with a net profit of 6.337 billion yuan, reflecting strong growth [4] - Bai Li Tian Heng reported a staggering 936.31% increase in revenue to 5.823 billion yuan, turning a profit due to a significant upfront payment from a global pharmaceutical partner [4] - Shen Zhou Cell's revenue reached 2.513 billion yuan, marking a 33.13% increase, with the company achieving profitability for the first time [5] Market Catalysts - The innovative drug sector is being catalyzed by various factors, including overseas licensing, domestic policy support, and clinical data advancements [7] - Recent policies in Beijing and Shenzhen aim to accelerate innovation in the pharmaceutical industry, offering financial incentives for successful drug approvals [7] - Investment trends show a significant increase in domestic innovative drug financing, with a 51.78% year-on-year growth in March [7] Future Outlook - Industry experts believe that continued policy support will provide better development opportunities for differentiated innovative drugs in China [8] - The focus on innovation and internationalization remains a core strategy for the industry, with expectations for faster approval processes and supportive pricing mechanisms [8]

证券代码：688506 证券简称：百利天恒 公告编号：2025-037 四川百利天恒药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 本次股东大会由公司董事会召集，会议由公司半数以上的董事共同推举的董 事张苏娅女士主持。会议采用现场投票和网络投票相结合的表决方式。本次股东 大会的召集和召开程序、出席会议人员的资格和召集人资格、会议的表决程序和 表决结果均符合《公司法》及《公司章程》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 30 日 （二） 股东大会召开的地点：成都市高新区高新国际广场 B 座 10 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 241 | | --- | --- | | 普通股股东人数 | 241 | | 2、出席会议的股东所持 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于四川百利天恒药业股份有限公司 2024 年年度股东大会的法律意见书 致：四川百利天恒药业股份有限公司 2. 根据《股东大会通知》，本次股东大会采取现场投票与网络投票相结合的 方式召开。 本次股东大会现场会议于 2025 年 4 月 30 日 14:30 时在成都市高新区高新国 际广场 B 座 10 楼会议室召开。董事长因其他工作安排未能现场出席本次股东大 会，根据《公司法》《股东会规则》及《公司章程》的规定，由贵公司半数以 上的董事共同推举的董事张苏娅女士主持。 北京君合（成都）律师事务所（以下简称"本所"）受四川百利天恒药业 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）等中华人民共和国现行有效的有关法律、行政法规、部门规章、规范性 文件（以下合称"法律法规"，仅为本法律意见书法律 ...